Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADCOLD is a fixed-dose combination medication manufactured and marketed by Adwin Life Care, primarily indicated for the symptomatic relief of the common cold, influenza, and allergic rhinitis. It typically contains a combination of three active pharmaceutical ingredients: paracetamol (acetaminophen), phenylephrine hydrochloride, and chlorpheniramine maleate. Paracetamol acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Phenylephrine is a sympathomimetic agent that serves as a nasal decongestant by specifically targeting alpha-1 adrenergic receptors to induce vasoconstriction in the nasal mucosa. Chlorpheniramine maleate is a first-generation alkylamine antihistamine that provides relief from sneezing, watery eyes, and runny nose by competing with histamine for H1-receptor sites on effector cells. The product is positioned as a finished commercial pharmaceutical rather than an investigational candidate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ADCOLD.